Menopause and HRT — structured oral station (12 minutes)

Opening prompt — "How do you confirm her diagnosis, and what would you offer her?"

Model response — clinical diagnosis, risk-stratified HRT: ^[1][3]

• "Her diagnosis is menopause, made clinically — she is over 45 with characteristic symptoms and amenorrhoea; I would not order an FSH or any blood test to confirm it."
• "Because she has a uterus and her BMI is over 30 with a family history of VTE, I would offer combined HRT with transdermal oestrogen — a patch or gel — plus micronised progesterone, which is VTE-neutral."
• "I would also offer separate vaginal oestrogen for her vaginal dryness if systemic HRT does not fully control it."

Probe 1 — "She is frightened HRT will give her breast cancer. Walk her through the evidence."

• "The breast-cancer fear comes from the 2002 WHI combined-HRT trial, which showed a breast cancer hazard ratio of 1.26. But that trial studied women with a mean age of 63, many a decade past menopause — not her."
• "The oestrogen-alone arm, in women who had had a hysterectomy, showed a breast cancer hazard ratio of 0.77 — a possible reduction. So oestrogen-only does not carry the same breast signal as combined HRT."
• "The 18-year follow-up showed all-cause mortality was unchanged (HR 0.99) — HRT did not shorten life. For her, in her early fifties, the benefit-risk balance is favourable."^[2]

Probe 2 — "Why transdermal, specifically?"

• "Oral oestrogen increases VTE risk — the ESTHER study found an odds ratio of 4.2 for oral versus 0.9 for transdermal. With her BMI over 30 and family history, transdermal is the safer route. Micronised progesterone carries an OR of 0.7, VTE-neutral, versus 3.9 for norpregnane derivatives — so I choose it over older progestogens."^[3]

Probe 3 — "How long should she take HRT, and what is the timing hypothesis?"

• "The timing hypothesis (ELITE) is that oestrogen protects the vasculature when started close to menopause but not a decade later. ELITE showed estradiol slowed carotid intima-media thickness when started within 6 years of menopause (P = 0.008) but not at 10-plus years."
• "She is 51, recently menopausal — she is squarely in the window of opportunity. I would continue HRT while her symptoms persist and the balance remains favourable, reviewing at 3 months then annually."^[4]

Probe 4 — "She asks if the HRT will stop her getting pregnant."

• "HRT is not contraceptive. She is perimenopausal and could still conceive. I would combine the HRT with an appropriate contraceptive method until she reaches age 55, when natural fertility can be assumed to have ceased."^[1]

Probe 5 — "She bursts into tears and says she feels she is 'falling apart'. What do you do?"

This is a scored communication domain — demonstrate it out loud: ^[1]

• Move to her eye level, use her name, acknowledge the distress: "What you are feeling is real and common — the sleep loss, the mood, the dryness, they all feed each other, and none of it means you are falling apart. This is menopause, it is treatable, and we will get you through it together."
• Offer a clear plan with a 3-month review and a named contact between visits. Address each symptom she raised. Normalise her experience without dismissing it.

Probe 6 — "How would your advice differ for a 33-year-old with the same symptoms?"

• "At 33, this would be premature ovarian insufficiency, not natural menopause. I would confirm it with two FSH levels over 25 IU/L at least 4 weeks apart, and her HRT would run until age 51 — physiologic replacement, not menopausal HRT. The WHI numbers would not apply to her, and withholding HRT would be the error."^[1]